Elorac, Inc. Announces Acquisition of All World-wide Rights to Cidoxepin
10/19/2010 9:14:44 AM
VERNON HILLS, Ill.--(BUSINESS WIRE)--Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, is pleased to announce that it has acquired world-wide rights to the active agent Cidoxepin from Gideon Pharmaceuticals. Cidoxepin is the cis-isomer of the widely prescribed tricyclic compound doxepin. Cidoxepin has significant norepinephrine and serotonin reuptake inhibitor activity, as well as being the most potent Histamine-1 (H1) blocker ever discovered.